Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Last trade$1.15
Day change+$0.025 (+2.23%)
Day range$1.13 – $1.24
Volume12,824
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.72M
Price / earnings
—
Price / book
0.05×
Price / sales
—
EV / sales
—
EV / EBITDA
0.41×
Profitability
Earnings per share
-$6.23
Return on assets
-23.66%
Return on equity
-26.9%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.72×
Quick ratio
8.72×
Cash ratio
1.3×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ENLV, quarterly periods
Line item
Q4 FY2020 Dec 31, 2020
Q3 FY2020 Sep 30, 2020
Q2 FY2020 Jun 30, 2020
Q1 FY2020 Mar 31, 2020
Q4 FY2019 Dec 31, 2019
Q3 FY2019 Sep 30, 2019
Q2 FY2019 Jun 30, 2019
Q1 FY2019 Mar 31, 2019
Revenue
—
—
—
—
—
—
—
—
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
—
—
—
—
—
—
—
—
Selling, general and administrative
$1.55M
$757K
$873K
$524K
$1.09M
$545K
$601K
$784K
Research and development
$2.15M
$1.2M
$1.36M
$1.37M
$1.75M
$1.58M
$696K
$1.58M
Total operating expenses
$3.7M
$1.96M
$2.23M
$1.9M
$2.84M
$2.12M
$1.3M
$2.36M
Operating income
-$3.7M
-$1.96M
-$2.23M
-$1.9M
-$2.84M
-$2.12M
-$1.3M
-$2.36M
Interest expense
—
-$223K
-$897K
-$2K
—
-$342K
-$202K
-$358K
Income before taxes
-$5.86M
-$2.13M
-$3.04M
-$794K
-$2.87M
-$2.39M
-$1.46M
-$2.67M
Income taxes
—
—
—
—
—
—
—
—
Net income
-$5.86M
-$2.13M
-$3.04M
-$794K
-$2.87M
-$2.39M
-$1.46M
-$2.67M
Net income attributable to common shareholders
-$3.59M
-$2.13M
-$3.04M
-$794K
-$1.92M
-$2.39M
-$1.46M
-$2.67M
EBITDA
-$3.7M
-$1.89M
-$2.17M
-$1.84M
-$2.84M
-$2.07M
-$1.25M
-$2.32M
Basic earnings per share
-$103.20
-$38.40
-$55.20
-$16.80
-$74.40
-$55.20
-$33.60
-$165.60
Diluted earnings per share
-$103.20
-$38.40
-$55.20
-$16.80
-$74.40
-$55.20
-$33.60
-$165.60
Recent news
Company coverage with links to the original publishers.
RAIN, an Arbitrum-based prediction market protocol, announced $200 million in ecosystem commitments through a partnership with Enlivex and $100 million in liquidity expansion ($50M USDT, $50M RAIN). The protocol is preparing for Version 2 launch featuring permissionless market creation, AMMs, on-chain order books, and AI-assisted market resolution, with plans for major expansion around the FIFA World Cup.
Enlivex Therapeutics received a notice of allowance for a Japanese patent application covering the use of its Allocetra™ product in treating osteoarthritis, a common and debilitating condition with limited treatment options.
Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares (or ordinary share equivalents in lieu thereof) and clinical milestone-linked warrants, composed of Series A warrants to purchase up to 3,571,429 ordinary shares and Series B warrants to purchase up to 3,571,429 ordinary shares, at a purchase price of $1.40 per ordinary share (or ordinary share equivalents in lieu thereof) and associated warrants, for aggregate gross proceeds of approximately $5.0 million.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.